Eagle Bluffs Wealth Management LLC Acquires 124 Shares of Abbott Laboratories (NYSE:ABT)

Eagle Bluffs Wealth Management LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,216 shares of the healthcare product maker’s stock after purchasing an additional 124 shares during the quarter. Eagle Bluffs Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,455,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Rappaport Reiches Capital Management LLC increased its stake in Abbott Laboratories by 0.8% in the 4th quarter. Rappaport Reiches Capital Management LLC now owns 12,287 shares of the healthcare product maker’s stock worth $1,352,000 after purchasing an additional 94 shares during the period. Patriot Investment Management Group Inc. increased its stake in shares of Abbott Laboratories by 3.1% during the fourth quarter. Patriot Investment Management Group Inc. now owns 3,236 shares of the healthcare product maker’s stock valued at $356,000 after buying an additional 96 shares during the period. Avion Wealth increased its stake in shares of Abbott Laboratories by 19.4% during the fourth quarter. Avion Wealth now owns 591 shares of the healthcare product maker’s stock valued at $65,000 after buying an additional 96 shares during the period. Shepherd Financial Partners LLC boosted its position in shares of Abbott Laboratories by 4.5% during the fourth quarter. Shepherd Financial Partners LLC now owns 2,275 shares of the healthcare product maker’s stock valued at $250,000 after purchasing an additional 99 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC boosted its position in shares of Abbott Laboratories by 0.5% during the first quarter. Stonebridge Capital Advisors LLC now owns 20,029 shares of the healthcare product maker’s stock valued at $2,371,000 after purchasing an additional 100 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Insider Activity at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now directly owns 18,760 shares in the company, valued at $2,223,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now directly owns 18,760 shares in the company, valued at approximately $2,223,060. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,435 shares of company stock worth $6,451,298. Insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Evercore ISI lifted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $128.00 target price on shares of Abbott Laboratories in a report on Wednesday, February 14th. Citigroup lifted their price target on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Barclays raised their price objective on Abbott Laboratories from $133.00 to $141.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Finally, Raymond James lifted their price target on Abbott Laboratories from $124.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $122.14.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock traded up $0.87 on Tuesday, hitting $109.76. 5,013,687 shares of the company were exchanged, compared to its average volume of 5,556,025. The stock has a market capitalization of $190.45 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 2.63 and a beta of 0.74. The company has a 50-day moving average price of $114.67 and a 200 day moving average price of $107.51. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 EPS for the quarter, meeting analysts’ consensus estimates of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The firm had revenue of $10.24 billion for the quarter, compared to analysts’ expectations of $10.19 billion. During the same period in the prior year, the firm posted $1.03 earnings per share. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. As a group, sell-side analysts predict that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is presently 67.48%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.